Konark Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 19 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -17.84%
- Profit Growth -70.76%
- Ebitda -47.47%
- Net Worth 2.92%
- Total Assets 12.48%
About Konark Lifesciences
Konark Lifesciences Private Limited (KLPL) is a Private Limited Indian Non-Government Company incorporated in India on 04 January 2006 and has a history of 19 years and one month. Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Hema Shah and Trupti Shah serve as directors at the Company.
Company Details
-
Location
Ahmedabad, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24230GJ2006PTC047447
-
Company No.
047447
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
04 Jan 2006
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
What products or services does Konark Lifesciences Private Limited offer?
Konark Lifesciences Private Limited offers a wide range of products and services, including Brain & Nervous System Drugs, Psychotherapeutic Agents, Antidepressant & Anti Anxiety Medicines.
Who are the key members and board of directors at Konark Lifesciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Hema Shah
|
Additional Director | 16-Nov-2021 | Current |
|
Trupti Shah
|
Additional Director | 16-Nov-2021 | Current |
Financial Performance of Konark Lifesciences.
Konark Lifesciences Private Limited, for the financial year ended 2019, experienced significant reduction in revenue, with a 17.84% decrease. The company also saw a substantial fall in profitability, with a 70.76% decrease in profit. The company's net worth moved up by a moderate rise of 2.92%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Konark Lifesciences?
In 2019, Konark Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Konark Lifesciences?
Unlock and access historical data on people associated with Konark Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Konark Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Konark Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
